CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage. Between 74-89% of retail investor accounts lose money when trading CFDs. You should consider whether you understand how CFDs work and whether you can afford to take the high risk of losing your money. Please refer to our Risk Disclosure Statement
Open platformOpen platform

PTC Therapeutics Presents 2026 Total Revenue Guidance of $1.29 Billion-$1.32 Billion

By Public Technologies
  • PTC Therapeutics projects 2026 total revenue of $1.29 billion–$1.32 billion, with operating expenses of $680 million–$720 million.
  • Product revenue guidance of $960 million–$990 million represents 64%–69% year-over-year growth.
  • Sephience generated $458 million in year-to-date global revenue during its first full launch year.
  • Cash totaled $2.1 billion, with cash flow breakeven targeted for the year.
  • The ST-920 gene therapy application for accelerated approval in Fabry disease is expected to be completed in the fourth quarter.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. PTC Therapeutics Inc. published the original content used to generate this news brief on October 29, 2026, and is solely responsible for the information contained therein.

Capital Com is an execution-only service provider. The present material must be regarded as marketing communication and should not be interpreted as investment research or investment advice. Any opinion that may be provided on this page does not constitute a recommendation by Capital Com or its agents. We do not make any representations or warranty on the accuracy or completeness of the information that is provided on this page. If you rely on the information on this page, then you do so entirely at your own risk